Jonsson Comprehensive Cancer Center

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Employees: -

Market Cap: -

Website: http://www.cancer.ucla.edu

Clinical Trials

Cytogenetic Study of Ocular Melanoma

Completed

Conditions: Choroidal Melanoma

First Posted Date: 2006-06-27

Last Posted Date: 2021-03-29

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 95

Registration Number: NCT00344799

Locations: 🇺🇸
Jules Stein Eye Institute, Los Angeles, California, United States

PHA-739358 in Treating Patients With Chronic Myelogenous Leukemia That Relapsed After Imatinib Mesylate or c-ABL Therapy

Phase 2

Conditions: Leukemia

First Posted Date: 2006-06-12

Last Posted Date: 2013-12-18

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 16

Registration Number: NCT00335868

Locations: 🇺🇸
Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, California, United States

PET Scan Combined With CT Scan in Evaluating Treatment Response in Patients Undergoing Treatment for Bone Cancer or Soft Tissue Sarcoma

Not Applicable

Completed

Conditions: Sarcoma

Interventions: Procedure: positron emission tomography computed tomography (PET/CT)

First Posted Date: 2006-06-12

Last Posted Date: 2020-07-31

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 120

Registration Number: NCT00335751

Locations: 🇺🇸
Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, California, United States

AMG 706 and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma

Phase 1

Conditions: Lung Cancer
Lymphoma
Lymphoproliferative Disorder
Unspecified Adult Solid Tumor, Protocol Specific

First Posted Date: 2006-05-11

Last Posted Date: 2013-09-17

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 18

Registration Number: NCT00324597

Locations: 🇺🇸
Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, California, United States

Bevacizumab and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer

Phase 2

Conditions: Kidney Cancer

First Posted Date: 2006-03-13

Last Posted Date: 2014-01-10

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 65

Registration Number: NCT00301990

Locations: 🇺🇸
Norris Cotton Cancer Center at Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States
🇺🇸
Cardinal Bernardin Cancer Center at Loyola University Medical Center, Maywood, Illinois, United States
🇺🇸
Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, California, United States

and more 8 locations

Volociximab and Erlotinib in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

Phase 2

Conditions: Lung Cancer

First Posted Date: 2006-01-18

Last Posted Date: 2013-12-19

Lead Sponsor: Jonsson Comprehensive Cancer Center

Registration Number: NCT00278187

Locations: 🇺🇸
Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, California, United States

Bortezomib in Treating Patients With Metastatic Kidney Cancer

Phase 2

Completed

Conditions: Kidney Cancer

Interventions: Drug: bortezomib

First Posted Date: 2006-01-13

Last Posted Date: 2020-09-01

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 4

Registration Number: NCT00276614

Locations: 🇺🇸
Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, California, United States

Epoetin Alfa in Treating Patients With Anemia Who Are Undergoing Chemotherapy for Cancer

Phase 2

Completed

Conditions: Anemia
Leukemia
Lymphoma
Lymphoproliferative Disorder
Multiple Myeloma and Plasma Cell Neoplasm
Precancerous Condition
Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Biological: epoetin alfa

First Posted Date: 2005-11-21

Last Posted Date: 2012-10-04

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 89

Registration Number: NCT00255749

Locations: 🇺🇸
Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, California, United States

Stent Placement With or Without Photodynamic Therapy Using Porfimer Sodium as Palliative Treatment in Treating Patients With Stage III or Stage IV Cholangiocarcinoma That Cannot Be Removed By Surgery

Phase 3

Withdrawn

Conditions: Cholangiocarcinoma of the Extrahepatic Bile Duct
Cholangiocarcinoma of the Gallbladder
Unresectable Extrahepatic Bile Duct Cancer
Unresectable Gallbladder Cancer
Recurrent Extrahepatic Bile Duct Cancer
Recurrent Gallbladder Cancer

First Posted Date: 2005-11-15

Last Posted Date: 2013-04-04

Lead Sponsor: Jonsson Comprehensive Cancer Center

Registration Number: NCT00253617

Locations: 🇺🇸
Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, California, United States
🇨🇦
Axcan Pharma, Incorporated, Mont-Saint-Hilaire, Quebec, Canada

Azacitidine and Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes

Phase 1

Terminated

Conditions: Leukemia
Myelodysplastic Syndromes

Interventions: Drug: arsenic trioxide
Drug: azacitidine

First Posted Date: 2005-10-06

Last Posted Date: 2020-07-31

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 1

Registration Number: NCT00234000

Locations: 🇺🇸
Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, California, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy